*3.2. Included Studies and Trials Characteristics*

The main characteristics of the included trials are outlined in Table 1. The three included studies were published between 2011 and 2016 and 92 patients received psilocybin with doses ranging from 0.2 to 0.4 mg/kg, depending on the trials. The different units used to measure doses (some of them depending on the weight of the patients) made results standardization difficult. Patients had depression and anxiety associated with life-threatening diseases, namely aggressive oncologic conditions. Although psilocybin is a natural substance found in some mushrooms, it was synthesized (in the laboratory) for the trials and was administered in the form of oral capsules. Concerning the duration of the intervention, results were usually assessed through the scales, days after the administration of psilocybin and in a longer follow-up, in some cases up to three months.
